Matthew Choy

Cooley advised Contentsquare, an all-in-one experience intelligence platform, on its definitive agreement to acquire Loris AI, a conversation intelligence platform, to give business leaders a deeper, more accurate view of the full customer journey – from click to conversation.

Cooley advised Dynavax Technologies Corporation (Nasdaq: DVAX), a commercial-stage biopharmaceutical company developing and commercializing innovative vaccines, on its successful proxy contest against Deep Track Capital.

Cooley advised Araris Biotech, a Swiss biotechnology company developing next-generation antibody-drug conjugates, on its definitive agreement to be acquired by Japan-based Taiho Pharmaceutical for up to $1.14 billion in cash.

Cooley advised the special committee of Checkpoint Therapeutics’ (Nasdaq: CKPT) board of directors in connection with Checkpoint’s definitive agreement to be acquired by Sun Pharmaceutical Industries (NSE: SUNPHARMA) for up to $416 million in cash and contingent value rights.

Cooley advised Personalis, a company transforming the active management of cancer through breakthrough personalized testing, on its expanded commercial relationship with Tempus AI, including an equity investment by Tempus into Personalis.